Adil Daud, MD
As researchers continue to explore immune checkpoints as targets for anticancer therapies, the IDO pathway has emerged as the leading contender to yield the next batch of new drugs in the field. Clinical trial results thus far have been particularly promising for IDO inhibitors combined with antibodies that target the PD-1/ PD-L1 pathway.
). This offers multiple opportunities for targeting the tumorigenic activities of aberrant IDO signaling.
“Now, this current generation of inhibitors is in testing, and they seem to be relatively nontoxic when they’re added to PD-1,” he said. “I think that’s something exciting considering all the immune checkpoint combinations that people are talking about. It seems like they can be combined and have a reasonable rate of activity, with the caveat that, currently, we are just talking about phase II trials.”
The most advanced agent under study is epacadostat, an orally available inhibitor of IDO1. Findings from early-phase studies into epacadostat have been promising, particularly in melanoma, where the drug is being paired with the PD-1 inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo) in separate studies.
... to read the full story